vTv Therapeutics

VTVT65

$14.18arrow_drop_up0.13%$0.01

VTVT65

$14.18

arrow_drop_up0.13%$0.01

Performance History

Key Stats
Open	$14.65
Prev. Close	$14.83
EPS	-4.37
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$37.04M
PE Ratio	-

	LOW	HIGH
Day Range	14.11	15.31
52 Week Range	7.38	30.99

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.37

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About vTv Therapeutics (VTVT)

vTv Therapeutics Inc (VTVT) is a biopharmaceutical company that develops innovative therapies to treat various diseases, with a focus on Alzheimer's disease (AD) and diabetes. The company's main goal is to improve patients' lives by advancing its pipeline of diverse drug candidates. With a market capitalization of [vTv Therapeutics Inc, VTVT market cap], the company is committed to addressing unmet medical needs.

One key aspect of vTv Therapeutics Inc's strategy is its smart analysis of the pharmaceutical industry. By analyzing market trends, competitive landscapes, and regulatory environments, the company aims to make informed decisions and drive its drug development programs forward. This intelligent approach enables vTv Therapeutics Inc to position itself favorably within the industry.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Paul J. Sekhri M.Sc., MSc
Headquarters: High Point
Employees: 13
Exchange: NASDAQ

Keep an eye on vTv Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is vTv Therapeutics 's (VTVT) price per share?

The current price per share for vTv Therapeutics (VTVT) is $14.18. The stock has seen a price change of $0.02 recently, indicating a 0.13% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for vTv Therapeutics (VTVT)?

For vTv Therapeutics (VTVT), the 52-week high is $30.99, which is 118.55% from the current price. The 52-week low is $7.38, the current price is 92.14% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is vTv Therapeutics (VTVT) a growth stock?

vTv Therapeutics (VTVT) has shown an average price growth of -6.03% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying vTv Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is vTv Therapeutics (VTVT) stock price performance year to date (YTD)?

As of the latest data, vTv Therapeutics (VTVT) has a year-to-date price change of 31.3%. Over the past month, the stock has experienced a price change of 1.29%. Over the last three months, the change has been -13.8%. Over the past six months, the figure is -51.12%. Looking at a longer horizon, the five-year price change stands at -76.83%.

help

Is vTv Therapeutics (VTVT) a profitable company?

vTv Therapeutics (VTVT) has a net income of -$20.25M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.29K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$25.5M. Furthermore, the EBITDA is -$22.77M.

help

What is the market capitalization of vTv Therapeutics (VTVT)?

vTv Therapeutics (VTVT) has a market capitalization of $37.04M. The average daily trading volume is 14.71, indicating the stock's liquidity and investor engagement.